

Substitute for form 1449A/PTO

~~(Use as many sheets as necessary)~~

1

of

3

Application Number

10/567,424

Filing Date

12/9/2008

First Named Inventor

Mulley et al.

Art Unit

1649

Examiner Name

Kolker, Daniel E.

Attorney Docket Number

1386/23

[illegible][illegible]

Date _____

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Beaumanoir, In: Epileptic Syndromes in Infancy, Childhood and Adolescence, 2 nd ed., Roger J BM et al. editor, London: John Libbey & Co. Ltd., pgs. 113-136 (2002).	
	4	Blume, W. T., "Childhood brain tumors presenting as chronic uncontrolled focal seizure disorders," Ann. Neurol., Vol. 4, pgs. 541-547 (1978).	
	5	Blume et al., "Childhood Brain Tumors Presenting as Chronic Uncontrolled Focal Seizure Disorders," Annals of Neurology, Vol. 12, No. 6, pgs. 538-541 (December 1982).	
	6	Burnstine et al., "Multifocal Independent epileptiform discharges in children: Ictal correlates and surgical therapy," Neurology, Vol. 41, pgs. 1223-1228 (1991).	
	7	Doose et al., "Severe idiopathic generalized epilepsy of infancy with generalized tonic-clonic seizures," Neuropediatrics, Vol. 29, pgs. 229-238 (1998).	
	8	Dravet et al., In: Epileptic Syndromes in Infancy, Childhood and Adolescence, 3 rd ed., Eastleigh: John Libbey & Co., Ltd. Pgs. 81-103 (2002).	
	9	GenBank Accession No. AC0100127, NCBI Database, National Center for Biotechnology Information, National Library of Medicine, NIH (Bethesda, MD, USA), GI: 11597116, 09 May 2001.	
	10	GenBank Accession No. AC0100127, NCBI Database, National Center for Biotechnology Information, National Library of Medicine, NIH (Bethesda, MD, USA), GI: 11597116, 08 April 2005	
	11	Genbank accession number AF225985.	
	12	Interview Summary corresponding to U.S. Patent Application Serial No. 12/696,769 dated February 18, 2011	
	13	Lossin C. Brain and Development (2009) vol. 31, pages 114-130.	
	14	Malik et al., "Multifocal Independent Spike Syndrome (MISS): An Identifiable and Predictable Electroclinical Syndrome," Neurology, Vol. 39, Suppl. 1, pg. 189 (1989).	
	15	Markand, O. N., "Slow spike-wave activity in EEG and associated clinical features: often called 'Lennox' or 'Lennox-Gastaut' syndrome," Neurology, Vol. 27, pgs. 746-757 (1977).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	Noriega-Sanchez et al., "Clinical and electroencephalographic correlation of independent multifocal spike discharges," Neurology, Vol. 26, pgs. 667-672 (1976).	
	17	Notice of Allowance corresponding to U.S. Patent Application Serial No. 12/696,769 dated March 21, 2011.	
	18	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 12/696,769 dated August 5, 2010.	
	19	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 12/696,769 dated November 29, 2010.	
	20	Office Action corresponding to U.S. Patent Application Serial No. 12/767,523 dated May 16, 2011.	
	21	Office Action corresponding to U.S. Patent Application Serial No. 11/922,377 dated May 25, 2011.	
	22	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 12/767,523 dated August 25, 2011.	
	23	Ohmori et al., "Is phenotype difference in severe myoclonic epilepsy in infancy related to SCN1A mutations?," Brain Dev., Vol. 25, pgs. 488-493 (2003).	
	24	Orkin et al. "Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy", NIH, 1995	
	25	Thomas et al., "Progress and Problems with the Use of Viral Vectors for Gene Therapy," Nature, Vol. 4, pgs. 346-358 (2003).	
	26	Verma et al., "Gene therapy promises, problems and prospects," Nature, Vol. 389, pgs. 239-242 (1997).	
	27	Yamatogi et al., "Severe Epilepsy with Multiple Independent Spike Foci," J. Clin. Neurophysiol., Vol. 20, pgs. 442-448 (2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.